• Novel Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-08-24

  Jeon and colleagues developed an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, identifying compound 8c as a nanomolar biochemical inhibitor with favorable drug-discovery properties. The study connected PDK4 inhibition with improved glucose tolerance, reduced allergic responses, and anticancer phenotypes in preclinical models, while also highlighting the need to distinguish target engagement from broader metabolic effects.

• Vasopressin Analogues: From Hormones to Peptides

  2026-08-23

  Glavaš and colleagues review how vasopressin structure, receptor signaling, and peptide engineering have produced analogues with distinct antidiuretic, vasoconstrictor, and therapeutic profiles. The review is especially useful for interpreting receptor-selective pharmacology, peptide stability, clinical translation, and the still preliminary antiviral hypotheses surrounding vasopressin analogues.

• METTL16–SENP3–LTF and Ferroptosis Resistance in HCC

  2026-08-22

  Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma cells from ferroptosis by limiting the labile iron pool. The study connects m6A-dependent RNA regulation, de-SUMOylation, and iron handling across cellular, organoid, animal, and human-sample models, providing a mechanistic framework for ferroptosis-focused cancer research.

• Leupeptin Hemisulfate in Translational Research

  2026-08-22

  A mechanistic and strategic guide to using Leupeptin hemisulfate salt for protease activity regulation, protein degradation studies, autophagy, and carefully bounded antiviral research, while connecting assay design to metabolite-regulated TET2 workflows.

• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-08-21

  Song et al. show that murine norovirus uses the host membrane-rupture factor NINJ1 to selectively release the viral NS1 protein while also permitting broader damage-associated molecular pattern release. Combining CRISPR screening, infection models, protein-interaction analysis, mutagenesis, and mouse experiments, the study defines a caspase-3– and NINJ1-dependent unconventional secretion pathway with implications for host–virus biology.

• Protease Inhibitor Cocktail for DFCP1–ATGL Assays

  2026-08-20

  Protect DFCP1, ATGL, and associated lipid-droplet proteins from extraction-induced degradation with a broad-spectrum, water-soluble inhibitor mixture. This guide translates the DFCP1–ATGL findings into practical workflows for Western blotting, Co-IP, imaging, kinase assays, and tissue lysate analysis while addressing EDTA-related compatibility limits.

• Protease Inhibitor Cocktail for Plant Extracts

  2026-08-20

  Protect labile plant proteins during extraction, immunoblotting, co-immunoprecipitation, and kinase assays with an EDTA-free, broad-spectrum formulation. This workflow guide shows how to preserve STOP1, STAR1, phosphoproteins, and other low-abundance targets while managing DMSO and assay-specific interference.

• Annexin V-PE Apoptosis Detection Kit Workflow

  2026-08-19

  Extend inflammatory monocyte experiments with a rapid live-cell death endpoint that distinguishes immune activation from membrane-level injury. This workflow shows how to apply Annexin V-PE staining to LPS and pentoxifylline studies while preserving flow cytometry and microscopy flexibility.

• Protease Inhibitor Cocktail: A Mechanistic Workflow

  2026-08-19

  Discover how a Protease Inhibitor Cocktail can preserve sample fidelity from lysis through mass spectrometry. This guide connects inhibitor-class selection with structural insights from Lassa virus spike research to improve assay interpretation and workflow design.

• Rotigotine in Parkinson’s Disease Research Workflows

  2026-08-18

  Rotigotine supports coordinated cell, animal, and formulation studies by combining broad dopaminergic activity with reported antioxidant and anti-inflammatory effects. This workflow-focused guide covers model selection, dosing, analytical controls, and troubleshooting for Parkinson’s disease and related neuropsychiatric research.

• Dual-Action Inhibition of p38α MAPK Dephosphorylation

  2026-08-18

  The reference study shows that some p38α MAPK inhibitors do more than occupy the kinase active site: they also accelerate WIP1-mediated dephosphorylation of the activation-loop phospho-threonine. Biochemical experiments and X-ray structures connect this effect to an inhibitor-stabilized, phosphatase-accessible activation-loop conformation, providing a mechanistic framework for designing more potent and selective kinase inhibitors.

• Formononetin and Oxaliplatin Neurotoxicity: Study Insights

  2026-08-17

  A 2026 NeuroToxicology study identified formononetin as a neuroprotective candidate that reduced oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway while preserving anticancer activity. The work also shows why neuroprotection must be evaluated alongside tumor-cell responses rather than inferred from antioxidant activity alone.

• Toremifene for Breast Cancer: Evidence and Context

  2026-08-17

  The reference review synthesizes clinical and pharmacologic evidence supporting toremifene as an endocrine option for postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is a balanced comparison of efficacy, safety, metabolism, and tissue-selective effects rather than a claim of superiority over tamoxifen or aromatase inhibitors.

• ROS-Degradable Lipid Nanoparticles for RAS Therapy

  2026-08-16

  Cai and colleagues developed a parallelly synthesized library of thioketal-containing lipids to create reactive oxygen species-responsive nanoparticles for tumor-selective mRNA delivery. Their lead formulation, BAmP-TK-12, enhanced delivery in cancer cells and enabled DUF5 mRNA to deplete mutant RAS, providing a mechanistically distinct strategy for blocking oncogenic signaling.

• Protease Inhibitor Cocktail: EDTA-Free Workflow

  2026-08-15

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic loss during protein extraction and downstream assays, including Western blotting, co-immunoprecipitation, phosphorylation analysis, and enzyme assays. Its EDTA-free design is appropriate when divalent cations must remain available, but it should not be treated as a complete substitute for EDTA when metalloprotease inhibition or chelation is required.

8481 records 1/566 page Next 12345 下5页 Last page